Inhibition of dengue virus by novel inhibitors of RNA-dependent RNA polymerase and protease activity
Dengue virus (DENV) is the leading mosquito-transmitted viral infection in the world. With more than 390 million new infections annually, and up to 1 million clinical cases with severe disease manifestations, there is an urgent need to develop new antiviral agents that inhibit DENV infectivity. Currently, no licensed antiviral drugs are available to block DENV infection and vector control efforts remain the only means to stop the spread of the infection.